Literature DB >> 10087053

Metallothionein-I/II knockout mice are sensitive to acetaminophen-induced hepatotoxicity.

J Liu1, Y Liu, D Hartley, C D Klaassen, S E Shehin-Johnson, A Lucas, S D Cohen.   

Abstract

The purpose of this study was to examine whether intracellular metallothionein (MT) protects against acetaminophen hepatotoxicity. MT-I/II knockout (MT-null) and control mice were given acetaminophen (150-500 mg/kg i.p.), and liver injury was assessed 24 h later. MT-null mice were more susceptible than controls to acetaminophen-induced lethality and hepatotoxicity, as evidenced by elevated serum enzyme activities and histopathology. Zinc pretreatment, a method of MT induction, protected against acetaminophen hepatotoxicity in control mice, but not in MT-null mice. The susceptibility of MT-null mice to acetaminophen hepatotoxicity was not due to the increased acetaminophen bioactivation, as cytochrome P-450 enzymes, and acetaminophen-reactive metabolites in bile and urine were not increased in MT-null mice. Western blots of liver cytosol indicated that acetaminophen covalent binding at 4 h increased with acetaminophen dose, but there was no consistent difference between control and MT-null mice. Acetaminophen injection depleted cellular glutathione similarly in both control and MT-null mice, but produced more lipid peroxidation in MT-null mice, as evidenced by the abundance of thiobarbiturate-reactive substances, and by immunohistochemical localization of 4-hydroxynonenal and malondialdehyde protein adducts. MT-null hepatocytes were more susceptible than control cells to oxidative stress and cytotoxicity produced by N-acetylbenzoquinoneimine, a reactive metabolite of acetaminophen, as determined by oxidation of 2', 7'-dichlorofluorescin diacetate and lactate dehydrogenase leakage. In summary, this study demonstrated that MT deficiency renders animals more vulnerable to acetaminophen-induced hepatotoxicity. The increased sensitivity does not appear to be due to increased acetaminophen activation, glutathione depletion, or covalent binding, but appears to be associated with the antioxidant role of MT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087053

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Role of metallothionein in nitric oxide signaling as revealed by a green fluorescent fusion protein.

Authors:  L L Pearce; R E Gandley; W Han; K Wasserloos; M Stitt; A J Kanai; M K McLaughlin; B R Pitt; E S Levitan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Hepatic proteome analysis of Atlantic salmon (Salmo salar) after exposure to environmental concentrations of human pharmaceuticals.

Authors:  Miriam Hampel; Esteban Alonso; Irene Aparicio; Juan Luis Santos; Michael Leaver
Journal:  Mol Cell Proteomics       Date:  2014-11-13       Impact factor: 5.911

3.  Changes in hepatic gene expression in response to hepatoprotective levels of zinc.

Authors:  Jie Liu; Zhan-Xiang Zhou; Wei Zhang; Matthew W Bell; Michael P Waalkes
Journal:  Liver Int       Date:  2009-03-23       Impact factor: 5.828

Review 4.  Chemistry and biology of mammalian metallothioneins.

Authors:  Milan Vašák; Gabriele Meloni
Journal:  J Biol Inorg Chem       Date:  2011-06-07       Impact factor: 3.358

5.  Expression profiling identifies novel gene targets and functions for Pdx1 in the duodenum of mature mice.

Authors:  Chin Chen; Eric Sibley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-01       Impact factor: 4.052

6.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.

Authors:  Brett A Howell; Yuching Yang; Rukmini Kumar; Jeffrey L Woodhead; Alison H Harrill; Harvey J Clewell; Melvin E Andersen; Scott Q Siler; Paul B Watkins
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-09       Impact factor: 2.745

7.  Mechanism of protection by metallothionein against acetaminophen hepatotoxicity.

Authors:  Chieko Saito; Hui-Min Yan; Antonio Artigues; Maria T Villar; Anwar Farhood; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2009-10-14       Impact factor: 4.219

8.  Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes.

Authors:  Scott A Reisman; Lauren M Aleksunes; Curtis D Klaassen
Journal:  Biochem Pharmacol       Date:  2009-04-01       Impact factor: 5.858

9.  Abrogation of nuclear factor-kappaB activation is involved in zinc inhibition of lipopolysaccharide-induced tumor necrosis factor-alpha production and liver injury.

Authors:  Zhanxiang Zhou; Lipeng Wang; Zhenyuan Song; Jack T Saari; Craig J McClain; Y James Kang
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

10.  Zinc Supplementation with Polaprezinc Protects Mouse Hepatocytes against Acetaminophen-Induced Toxicity via Induction of Heat Shock Protein 70.

Authors:  Tadashi Nishida; Shuzo Ohata; Chiaki Kusumoto; Shinsuke Mochida; Junya Nakada; Yoshimi Inagaki; Yoshiji Ohta; Tatsuya Matsura
Journal:  J Clin Biochem Nutr       Date:  2009-12-29       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.